Vitamin B conjugates are broadly studied in biological sciences. As light offers spatiotemporal control, we decided to develop a method for the preparation of vitamin B conjugates that release tethered molecules upon exposure to light. Herein, we report vitamin B derivatives possessing a photolabile linker suitable for conjugation with amines, azides, and alkynes. The potential applications of such conjugates are broad and include the delivery of drugs, labels, and imaging agents to their place of action and spatiotemporal release.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.orglett.1c00839 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuroprotective and inflammatory biomarkers in pediatric drug-resistant epilepsy: Interplay between GDNF, IL-1β and vitamin D 25-OH.
Narra J
December 2024
Department of Clinical Pathology, Faculty of Medicine, Universitas Imelda, Medan, Indonesia.
Drug-resistant epilepsy in pediatric patients is associated with neuroinflammation and neurodegeneration. Vitamin D 25-OH exerts neuroprotective effects, while glial cell line- derived neurotrophic factor (GDNF) and the proinflammatory cytokine interleukin-1β (IL-1β) are implicated in the mechanisms of neuroinflammation and epileptogenesis. The aim of this study was to investigate the relationship between vitamin D 25-OH, IL-1β, and GDNF levels with seizure severity and frequency in children with drug-resistant epilepsy.
View Article and Find Full Text PDFClinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Nat Rev Nephrol
January 2025
APHP, Reference Center for Rare Diseases of Calcium and Phosphate Metabolism, and Filière OSCAR, endo ERN and ERN BOND, Paris, France.
X-linked hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX gene, which is predominantly expressed in osteoblasts, osteocytes and odontoblasts. XLH is characterized by increased synthesis of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23), which results in renal phosphate wasting with consecutive hypophosphataemia, rickets, osteomalacia, disproportionate short stature, oral manifestations, pseudofractures, craniosynostosis, enthesopathies and osteoarthritis. Patients with XLH should be provided with multidisciplinary care organized by a metabolic bone expert.
View Article and Find Full Text PDFMechanistic implications of the Mediterranean diet in patients with newly diagnosed Crohn's disease- multi-omic results from a prospective cohort.
Gastroenterology
January 2025
Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel; Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Background: To decipher the mechanisms underlying the protective role of the Mediterranean diet (MED) in Crohn's disease (CD), we explored the implications of adherence to MED on CD course, inflammatory markers, microbial and metabolite composition.
Methods: Patients with newly diagnosed CD were recruited and followed prospectively. MED adherence was assessed by repeated food frequency questionnaires (FFQ), using a predefined IBDMED score, alongside validated MED adherence screeners.
sp. nov., a bacterium isolated from the roots of the aquatic plant .
Int J Syst Evol Microbiol
January 2025
Department of Biology, Slippery Rock University, Slippery Rock, Pennsylvania 16057, USA.
A polyphasic taxonomic study was carried out on strain T9W2-O, isolated from the roots of the aquatic plant . This isolate is rod-shaped, forms yellow/orange pigmented colonies and produces the pigment flexirubin. Nearly complete 16S rRNA gene sequence homology related the strain to , with 98.
View Article and Find Full Text PDFConstruction of antibiotic-free riboflavin producer in by metabolic engineering strategies with a plasmid stabilization system.
Synth Syst Biotechnol
June 2025
Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu 214122, China.
Riboflavin, an important vitamin utilized in pharmaceutical products and as a feed additive, is mainly produced by metabolically engineered bacterial fermentation. However, the reliance on antibiotics in the production process leads to increased costs and safety risks. To address these challenges, an antibiotic-free riboflavin producer was constructed using metabolic engineering approaches coupled with a novel plasmid stabilization system.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!